Clinical characteristics of the patients and results of ATO therapy and follow-up
| Patient no. . | Sex/age, y . | WBC, × 109/L . | Platelets, × 109/L . | Blasts/promyelocytes in BM, % . | t(15;17)/ PML/RARa . | Days to achieve HCR . | Treatment results . | Follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| 1 | F/6 | 2.6 | 18 | 69 | ND/+* | 48 | HCR | 76 |
| 2 | M/9 | 2.1 | 70 | 83 | ND/+* | 40 | HCR | 76 |
| 3 | F/9 | 18.9 | 38 | 82 | +/ND | 38 | HCR | 76 |
| 4 | M/12 | 38.6 | 50 | 96 | +/ND | — | ED | |
| 5 | F/5 | 4.8 | 35 | 84 | ND/+* | 41 | HCR, relapse, second HCR | 74 |
| 6 | M/11 | 1.3 | 102 | 86 | ND/+* | 40 | CR | 74 |
| 7 | M/15 | 5.7 | 31 | 86 | ND/+* | 29 | HCR, relapse, second HCR | 70 |
| 8 | M/4 | 10.7 | 39 | 84 | ND/+* | 43 | HCR | 64 |
| 9 | M/13 | 89.6 | 27 | 94 | +/ND | — | ED | — |
| 10 | F/6 | 3.8 | 30 | 65 | ND/+ | 26 | HCR | NA |
| 11 | M/12 | 20.6 | 42 | 84 | +/+ | 33 | HCR | 53 |
| 12 | M/7 | 2.2 | 52 | 47 | −/+ | 34 | HCR | 53 |
| 13 | M/12 | 1.0 | 45 | 76 | +/+ | 30 | HCR | 48 |
| 14 | F/15 | 4.7 | 10 | 90 | +/+ | 35 | HCR | 32 |
| 15 | F/5 | 12.7 | 35 | 82 | ND/+ | 35 | HCR | 25 |
| 16 | M/11 | 2.4 | 47 | 83 | +/+ | 30 | HCR | 25 |
| 17 | F/15 | 6.8 | 33 | 92 | +/+ | 41 | HCR | 25 |
| 18 | F/10 | 2.9 | 22 | 87 | +/+ | 55 | HCR | 23 |
| 19 | M/9 | 10.3 | 77 | 95 | +/+ | 51 | HCR, died in second relapse | 27 |
| Patient no. . | Sex/age, y . | WBC, × 109/L . | Platelets, × 109/L . | Blasts/promyelocytes in BM, % . | t(15;17)/ PML/RARa . | Days to achieve HCR . | Treatment results . | Follow-up, mo . |
|---|---|---|---|---|---|---|---|---|
| 1 | F/6 | 2.6 | 18 | 69 | ND/+* | 48 | HCR | 76 |
| 2 | M/9 | 2.1 | 70 | 83 | ND/+* | 40 | HCR | 76 |
| 3 | F/9 | 18.9 | 38 | 82 | +/ND | 38 | HCR | 76 |
| 4 | M/12 | 38.6 | 50 | 96 | +/ND | — | ED | |
| 5 | F/5 | 4.8 | 35 | 84 | ND/+* | 41 | HCR, relapse, second HCR | 74 |
| 6 | M/11 | 1.3 | 102 | 86 | ND/+* | 40 | CR | 74 |
| 7 | M/15 | 5.7 | 31 | 86 | ND/+* | 29 | HCR, relapse, second HCR | 70 |
| 8 | M/4 | 10.7 | 39 | 84 | ND/+* | 43 | HCR | 64 |
| 9 | M/13 | 89.6 | 27 | 94 | +/ND | — | ED | — |
| 10 | F/6 | 3.8 | 30 | 65 | ND/+ | 26 | HCR | NA |
| 11 | M/12 | 20.6 | 42 | 84 | +/+ | 33 | HCR | 53 |
| 12 | M/7 | 2.2 | 52 | 47 | −/+ | 34 | HCR | 53 |
| 13 | M/12 | 1.0 | 45 | 76 | +/+ | 30 | HCR | 48 |
| 14 | F/15 | 4.7 | 10 | 90 | +/+ | 35 | HCR | 32 |
| 15 | F/5 | 12.7 | 35 | 82 | ND/+ | 35 | HCR | 25 |
| 16 | M/11 | 2.4 | 47 | 83 | +/+ | 30 | HCR | 25 |
| 17 | F/15 | 6.8 | 33 | 92 | +/+ | 41 | HCR | 25 |
| 18 | F/10 | 2.9 | 22 | 87 | +/+ | 55 | HCR | 23 |
| 19 | M/9 | 10.3 | 77 | 95 | +/+ | 51 | HCR, died in second relapse | 27 |
ATO indicates arsenic trioxide; BM, bone marrow; CR, complete remission; ED, early death; F, female; HCR, complete hematologic remission; PML-RARa, promyelocytic leukemia-retinoic acid receptor-α; M, male; NA, lost to follow-up; ND, not done; WBC, white blood count; −, negative; +, positive; and —, not applicable.
PML/RARa was detected by fluorescence in situ hybridization.